oncology

Highly specific indications dominate cancer drug pipelineRecent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
This is why you should be excited for upcoming cancer researchAcute myeloid leukemia experts share promising new developments on the oncology horizon.
Four things payers need to know about acute myeloid leukemiaPhysicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.
Five rules for payer success in oncologyPayers must reinvent efforts to reduce cancer cost and increase quality for a value-based care world. Here’s five rules to follow.
FDA okays biosimilar for several cancers
FDA okays biosimilar for several cancersWhile FDA has approved a handful of biosimilar drugs, the agency just approved the first biosimilar that treats a variety of types of cancer.
Update: Immunotherapeutic options in advanced melanomaAt EADV, Dr. Simone Ribero reviews the latest data on new treatments for advanced melanoma.
Avelumab safety profile is “acceptable”Immunotherapy improves Merkel cell carcinoma, but questions remain.
First gene therapy for cancer approved: What health execs should knowThe first therapy based on gene transfer has been approved by the FDA. What’s next for healthcare executives?
Oral specialty drug options on the horizon
Oral specialty drug options on the horizonAs more specialty drugs are approved, cost control strategies are key.
Bundled payments on ‘pause,’ but not for longPolitical uncertainty plagues new payment arrangement, but private payers embrace new model.